<DOC>
	<DOCNO>NCT01632163</DOCNO>
	<brief_summary>Primary Objective : - To assess effect glycemic control lixisenatide comparison placebo add-on treatment basal insulin without metformin term HbA1c reduction period 24 week insufficiently control type 2 diabetic patient . Secondary Objectives : - To assess effect lixisenatide 24 week : - percentage patient reach HbA1c &lt; 7 % ≤6.5 % , - 2-hour postprandial plasma glucose ( PPG ) plasma glucose ( PG ) excursion standardize meal challenge test , - fast plasma glucose ( FPG ) , - change 7-point self-monitored plasma glucose ( SMPG ) profile ) , - body weight , - change daily basal insulin dose . - To assess lixisenatide safety tolerability . - To assess anti-lixisenatide antibody development .</brief_summary>
	<brief_title>Assessment Efficacy Safety Lixisenatide Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin</brief_title>
	<detailed_description>Maximum study duration approximately 35 week ± 9 day ( 2 week screen + 8 week run-in + 24 week double-blind treatment+ 3 day follow-up )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes mellitus ( T2DM ) diagnose least 1 year time screen visit insufficiently control basal insulin± metformin . Exclusion criterion : At screening : Age &lt; legal age adulthood . HbA1c &lt; 7 % &gt; 10.5 % . Basal insulin treatment stable regimen least 3 month stable dose ( ± 20 % ) least 15 U/day least 2 month prior screen visit . If metformin give , metformin treatment stable dose least 1.0 g/day least 3 month prior screen visit . History hypoglycemia unawareness . Body Mass Index ( BMI ) ≤20 kg/m² . Use oral injectable glucoselowering agent basal insulin metformin within 3 month prior time screen . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>